EDAP Schedules Webcast and Conference Call for Third Quarter 2012 Results
2012年11月7日 - 10:30PM
EDAP TMS SA (Nasdaq:EDAP), the global leader in therapeutic
ultrasound, announced today details relating to its third quarter
2012 results announcement, which will take place on Wednesday,
November 21, 2012, before the opening of the market.
EDAP will hold a conference call on Wednesday, November 21, 2012
at 8:30 a.m. EST to discuss the results. The dial-in numbers are
1-877-317-6789 for domestic callers and 1-412-317-6789 for
international callers. The conference ID number for both is
10020283. A live webcast of the conference call will be available
online from the investor relations page of the Company's corporate
website at www.edap-tms.com.
After the live webcast, the call will remain available on EDAP's
website, www.edap-tms.com, through December 21, 2012. In addition,
a telephonic replay of the call will be available until December 6,
2012. The replay dial-in numbers are 1-877-344-7529 for domestic
callers and 1-412-317-0088 for international callers. Please use
event passcode 10020283.
About EDAP TMS SA
EDAP TMS SA develops and markets Ablatherm(R), the most advanced
and clinically proven choice for high-intensity focused ultrasound
(HIFU) treatment of localized prostate cancer. HIFU treatment is
shown to be a minimally invasive and effective treatment option
with a low occurrence of side effects. Ablatherm-HIFU is generally
recommended for patients with localized prostate cancer (stages
T1-T2) who are not candidates for surgery or who prefer an
alternative option, or for patients who failed radiotherapy
treatment. Approved in Europe as a treatment for prostate cancer,
Ablatherm-HIFU (High Intensity Focused Ultrasound) is currently
undergoing evaluation in a multi-center U.S. Phase II/III clinical
trial under an Investigational Device Exemption (IDE) granted by
the FDA, the ENLIGHT U.S. clinical study. The Company also is
developing this technology for the potential treatment of certain
other types of tumors. EDAP TMS SA also produces and commercializes
medical equipment (the Sonolith(R) range) for treatment of urinary
tract stones using extra-corporeal shockwave lithotripsy (ESWL).
For more information on the Company, please visit
http://www.edap-tms.com, and http://www.hifu-planet.com.
Forward-Looking Statements
In addition to historical information, this press release may
contain forward-looking statements that involve risks and
uncertainties. Such statements are based on management's current
expectations and are subject to a number of uncertainties,
including the uncertainties of the regulatory process, and risks
that could cause actual results to differ materially from those
described in these forward-looking statements. Factors that may
cause such a difference include, but are not limited to, those
described in the Company's filings with the Securities and Exchange
Commission and in particular, in the sections "Cautionary Statement
on Forward-Looking Information" and "Risk Factors" in the Company's
Annual Report on Form 20-F. Ablatherm-HIFU treatment is in clinical
trials, but not FDA-approved or marketed in the United States.
CONTACT: Blandine Confort
Investor Relations / Legal Affairs
EDAP TMS SA
+33 4 72 15 31 72
bconfort@edap-tms.com
Investors:
Stephanie Carrington
The Ruth Group
646-536-7017
scarrington@theruthgroup.com
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 7 2024 まで 8 2024
EDAP TMS (NASDAQ:EDAP)
過去 株価チャート
から 8 2023 まで 8 2024